Tübingen University Children’s Hospital,
funding for an important clinical study
Every year across Europe, around 10,000 to 20,000 newborns suffer from a serious lack of oxygen during birth. Worldwide, the figure rises to as high as 1,000,000, compounded by fraught economic, and thus also medical conditions. An alarmingly high figure, not to mention an alarming picture in view of the dramatic health implications in some cases, which may result in lifelong disabilities.
The standard form of treatment, therapeutic hypothermia is not reliably guaranteed to help in case of seizures, intelligence development and infant movement disorders. The rediscovery of an old familiar medication for treating gout in adults promises success in specific cases. Tests on animals and previous small-scale studies point to a significant additional beneficial effect of its pharmaceutical formula in the treatment of small patients. However, complex clinical studies are necessary for the medication to be approved. These take time to furnish evidence of the efficacy and tolerance of the formula and are expensive. The Centre of Pediatric Clinical Studies, University Children’s Hospital Tübingen has been working on this promising study since 2016 in cooperation with 16 European partner institutions. The Covid-19 pandemic has also impacted on the projects, resulting in delays, absences and thus increased costs which jeopardise the continuation of this important study for the local team in Tübingen and in turn, better prospects of a cure for young patients. The MARGARETE MÜLLER-BULL FOUNDATION is conscious of what this would mean. It also knows that applications for funding must be submitted to potential sponsors BEFORE they start, because otherwise a new approval of funds is excluded. Tübingen’s funding needs are high and for this reason we have already shouldered a third of the sum. After all, we want the future to belong to our children, ALL of our children.